Trial Profile
AURORA 2: Aurinia Renal Response in Lupus With Voclosporin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Voclosporin (Primary) ; Mycophenolate mofetil; Steroids
- Indications Lupus nephritis
- Focus Adverse reactions; Registrational
- Acronyms AURORA 2
- Sponsors Aurinia Pharmaceuticals
- 15 Nov 2023 Results from the AURORA 1 and AURORA 2 assessing Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis, presented at the ACR Convergence 2023
- 15 Nov 2023 Results assessing the long-term renal impact of voclosporin at the histologic level with paired kidney biopsies from a subset of patients, presented at the ACR Convergence 2023.
- 07 Nov 2023 According to an Aurinia Pharmaceuticals media release, data from AURORA 2 extension study will be presented at the annual American College of Rheumatology Convergence 2023